{"id":10065,"date":"2020-03-23T14:52:19","date_gmt":"2020-03-23T14:52:19","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=10065"},"modified":"2020-12-14T17:58:16","modified_gmt":"2020-12-14T22:58:16","slug":"application-to-fda-for-lonafarnib-approval-is-done","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/pt\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","title":{"rendered":"O pedido de aprova\u00e7\u00e3o do lonafarnib ao FDA foi CONCLU\u00cdDO!"},"content":{"rendered":"<p>[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d3.22\u2033][et_pb_row _builder_version=\u201d3.25\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d3.25\u2033 custom_padding=\u201d|||\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text admin_label=\u201dFDA\u201d _builder_version=\u201d4.3.4\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d]<\/p>\n<p style=\"font-weight: 400;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10068  alignleft\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA-300x265.jpg\" alt=\"\" width=\"206\" height=\"182\" \/>O pedido de aprova\u00e7\u00e3o do lonafarnib ao FDA foi CONCLU\u00cdDO!\u00a0\u00a0\u00a0<\/strong><\/p>\n<p style=\"font-weight: 400;\">Em um momento dif\u00edcil para o nosso mundo, estou feliz em compartilhar um ponto positivo: a Eiger BioPharmaceuticals concluiu o envio de uma Nova Aplica\u00e7\u00e3o de Medicamento (NDA), buscando aprova\u00e7\u00e3o \u2014 na Europa e nos EUA \u2014 do medicamento lonafarnib como o primeiro tratamento para Prog\u00e9ria.<\/p>\n<p style=\"font-weight: 400;\">Esta submiss\u00e3o \u00e9 o resultado de doze anos de dados de pesquisa e quatro ensaios cl\u00ednicos, todos financiados pela PRF e poss\u00edveis gra\u00e7as \u00e0s crian\u00e7as corajosas e suas fam\u00edlias, bem como \u00e0 maravilhosa comunidade de doadores da PRF.<\/p>\n<p style=\"font-weight: 400;\">Voc\u00ea pode ler mais sobre esta not\u00edcia emocionante\u00a0<a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/PRF-Lonafarnib-NDA-Completion-Press-Release-final-PDF-3-23-20.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/PRF-Lonafarnib-NDA-Completion-Press-Release-final-PDF-3-23-20.pdf&amp;source=gmail&amp;ust=1585060548571000&amp;usg=AFQjCNE_6Qu8yUr9CDSuYvEVeGJXwXtlYA\">aqui<\/a>.<\/p>\n<p style=\"font-weight: 400;\">Nossa esperan\u00e7a \u00e9 que esse medicamento seja aprovado, permitindo que essas crian\u00e7as e jovens adultos tenham acesso ao lonafarnib \u2013 que demonstrou dar a eles cora\u00e7\u00f5es mais fortes e vidas mais longas \u2013 por prescri\u00e7\u00e3o, em vez de por meio de um ensaio cl\u00ednico.<\/p>\n<p style=\"font-weight: 400;\">Embora 2020 tenha come\u00e7ado como um ano dif\u00edcil para muitos, estamos felizes em compartilhar algumas boas not\u00edcias com voc\u00eas. Todos n\u00f3s da The Progeria Research Foundation trabalhamos incansavelmente para causar um impacto significativo na vida de crian\u00e7as e jovens adultos com Progeria.<\/p>\n<p style=\"font-weight: 400;\">OBRIGADO A TODOS por apoiarem a pesquisa que n\u00e3o apenas nos trouxe a esse ponto crucial, mas tamb\u00e9m nos permite continuar trabalhando para descobrir novos medicamentos que acabar\u00e3o curando essas crian\u00e7as extraordin\u00e1rias.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>Em um momento dif\u00edcil para o nosso mundo, estamos felizes em compartilhar um ponto positivo: a Eiger BioPharmaceuticals concluiu o envio de uma Nova Aplica\u00e7\u00e3o de Medicamento (NDA), buscando aprova\u00e7\u00e3o \u2014 na Europa e nos EUA \u2014 do medicamento lonafarnib como o primeiro tratamento para Prog\u00e9ria.<\/p>","protected":false},"author":2,"featured_media":10068,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-10065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/pt\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/pt\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-23T14:52:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-14T22:58:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"529\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"Application to FDA for lonafarnib approval is COMPLETE!\",\"datePublished\":\"2020-03-23T14:52:19+00:00\",\"dateModified\":\"2020-12-14T22:58:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"},\"wordCount\":294,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\",\"name\":\"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"datePublished\":\"2020-03-23T14:52:19+00:00\",\"dateModified\":\"2020-12-14T22:58:16+00:00\",\"description\":\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"width\":600,\"height\":529},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Application to FDA for lonafarnib approval is COMPLETE!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/pt\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"O pedido de aprova\u00e7\u00e3o do lonafarnib junto \u00e0 FDA est\u00e1 CONCLU\u00cdDO! - Funda\u00e7\u00e3o de Pesquisa da Progeria","description":"Em um momento dif\u00edcil para o mundo, temos o prazer de compartilhar uma not\u00edcia positiva: a Eiger BioPharmaceuticals concluiu o envio de um pedido de registro de novo medicamento (NDA, na sigla em ingl\u00eas), buscando aprova\u00e7\u00e3o \u2013 na Europa e nos EUA \u2013 para o medicamento lonafarnib como o primeiro tratamento para a Progeria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/pt\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","og_locale":"pt_PT","og_type":"article","og_title":"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation","og_description":"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/pt\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2020-03-23T14:52:19+00:00","article_modified_time":"2020-12-14T22:58:16+00:00","og_image":[{"width":600,"height":529,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"Application to FDA for lonafarnib approval is COMPLETE!","datePublished":"2020-03-23T14:52:19+00:00","dateModified":"2020-12-14T22:58:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"},"wordCount":294,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","articleSection":["News"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","url":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","name":"O pedido de aprova\u00e7\u00e3o do lonafarnib junto \u00e0 FDA est\u00e1 CONCLU\u00cdDO! - Funda\u00e7\u00e3o de Pesquisa da Progeria","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","datePublished":"2020-03-23T14:52:19+00:00","dateModified":"2020-12-14T22:58:16+00:00","description":"Em um momento dif\u00edcil para o mundo, temos o prazer de compartilhar uma not\u00edcia positiva: a Eiger BioPharmaceuticals concluiu o envio de um pedido de registro de novo medicamento (NDA, na sigla em ingl\u00eas), buscando aprova\u00e7\u00e3o \u2013 na Europa e nos EUA \u2013 para o medicamento lonafarnib como o primeiro tratamento para a Progeria.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","width":600,"height":529},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Application to FDA for lonafarnib approval is COMPLETE!"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Funda\u00e7\u00e3o de Pesquisa Progeria","description":"Pelas Crian\u00e7as \u2665 Pela Cura","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Funda\u00e7\u00e3o de Pesquisa Progeria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/pt\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/posts\/10065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/comments?post=10065"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/posts\/10065\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/media\/10068"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/media?parent=10065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/categories?post=10065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/tags?post=10065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}